Clinical Trials Logo

Opsoclonus-myoclonus Syndrome clinical trials

View clinical trials related to Opsoclonus-myoclonus Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00202930 Terminated - Neuroblastoma Clinical Trials

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus. Patients must have continued symptoms of opsoclonus, myoclonus and or ataxia despite surgical resection and a minimum of one month of steroid therapy. Evaluations include clinical symptoms of opsoclonus-myoclonus and ataxia as well as detailed evaluation of learning and development.